 |
|
Expression of Androgen Receptor, Epidermal Growth Factor Receptor, and Transforming Growth Factor  in Salivary Duct Carcinoma
Chun-Yang Fan, MD, PhD;
Mona F. Melhem, MD;
A. Sefik Hosal, MD;
J. Rubin Grandis, MD;
E. Leon Barnes, MD
Arch Otolaryngol Head Neck Surg. 2001;127:1075-1079.
Background Salivary duct carcinoma (SDC) is a rare, highly aggressive neoplasm
that primarily affects the major salivary glands. It is a distinct clinicopathological
entity characterized by its morphologic resemblance to ductal carcinoma of
the breast, a high incidence of regional lymph node metastasis, and distant
dissemination. Frequent expression of androgen receptor (AR) but not estrogen
receptor or progesterone receptor in SDCs suggests that SDC bears a close
immunophenotypic homology with prostatic carcinoma. An AR-mediated autocrine
growth pathway consisting of epidermal growth factor receptor (EGFR) and its
ligand, transforming growth factor  (TGF-), has been implicated
in the carcinogenesis of prostatic carcinoma. Androgens, in the presence of
AR, mediate their mitogenic effects on prostatic cancer cells by up-regulating
the transcriptional and translational activities of EGFR and TGF-.
Through an autocrine mode of action, TGF- produced in the tumor cells
binds to its receptor, EGFR, which is also expressed by these cells, resulting
in a proliferative response.
Objective To investigate whether a TGF-/EGFR autocrine pathway is present
in SDCs.
Design Retrospective analysis of the expression of AR, EGFR, and TGF-
in 12 SDCs.
Setting An academic medical center.
Results Salivary duct carcinoma expresses AR, TGF-, and EGFR in 11 (92%),
8 (67%), and 11 (92%) of 12 cases, respectively.
Conclusion An AR-mediated TGF-/EGFR autocrine pathway may be implicated
in the tumorigenesis of SDC.
From the Department of Pathology, University of Arkansas for Medical
Sciences, Little Rock (Dr Fan); Department of Pathology, Veterans Affairs
Medical Center, Pittsburgh, Pa (Dr Melhem); Department of Otolaryngology,
Hacettepe University Medical Faculty, Ankara, Turkey (Dr Hosal); and Departments
of Otolaryngology (Dr Grandis) and Pathology (Dr Barnes), University of Pittsburgh
School of Medicine, Pittsburgh, Pa.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Otolaryngology–Head & Neck Surgery Reader's Choice: Continuing Medical Education
Arch Otolaryngol Head Neck Surg. 2001;127(9):1146-1148.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands
Agulnik et al.
JCO 2007;25:3978-3984.
ABSTRACT
| FULL TEXT
Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers
Laurie and Licitra
JCO 2006;24:2673-2678.
ABSTRACT
| FULL TEXT
|
